Pharmaceutical News and Articles

Comprehensive and up-to-date drug news for both consumers and healthcare professionals.

Wegovy May Help Quiet Constant Food Cravings, Study Finds

WEDNESDAY, Sept. 17, 2025 A popular weight-loss drug may do more than help patients shed pounds. It could also help quiet the nonstop food cravings many people

Hair Samples May Help Spot Mental Health Risks in Sick Kids

WEDNESDAY, Sept. 17 2025 Children with chronic illnesses face extra challenges, and measuring stress through hair samples may help doctors predict which kids ar

Without Biannual Time Shift, Prevalence of Obesity, Stroke May Be Reduced

The prevalence of obesity and stroke would be reduced with permanent Standard Time (SDT) and Daylight Saving Time (DST) compared with the current Biannual Shift

GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity

Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with knee osteoart

Long COVID Linked to Abnormal Uterine Bleeding

Long COVID is associated with abnormal uterine bleeding (AUB), but not with impaired ovarian function, according to a study published online Sept. 16 in Nature

Digital Intervention Aids Psychological Outcomes With Inflammatory Rheumatic Diseases

A digital psychological intervention is safe and effective for individuals with inflammatory rheumatic diseases (IRDs), according to a study published online Se

Alcohol-Induced Deaths Almost Doubled From 1999 to 2024

Rates of alcohol-induced deaths among U.S. adults nearly doubled from 1999 to 2024, according to a study published online Sept. 17 in PLOS Global Public Health.

Lilly's Oral GLP-1, Orforglipron, is Successful in Third Phase 3 Trial, Triggering Global Regulatory Submissions This Year for the Treatment of Obesity

Eli Lilly and Company (NYSE LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial, evaluating orforglipron, an investigational oral GLP-

Regeneron Announces Positive Results from Phase 3 Trial of Cemdisiran in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) today announced that the primary and key secondary endpoints were met in the Phase 3 NIMBLE trial assessing invest

Discontinuation of Medical Cannabis Common in Musculoskeletal Pain

A number of patients with musculoskeletal pain discontinue medical cannabis (MC) within one year, with many discontinuing within the first three months, accordi

Popular Keywords